Vogenx (NASDAQ:VOGX) Announces Quarterly Earnings Results

Vogenx (NASDAQ:VOGX) announced its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, Zacks reports.

Vogenx Trading Up 2.2%

Shares of VOGX stock opened at $34.13 on Friday. Vogenx has a one year low of $12.95 and a one year high of $36.00.

Analyst Upgrades and Downgrades

VOGX has been the topic of several research reports. Wall Street Zen upgraded shares of Vogenx to a “hold” rating in a report on Saturday, August 22nd. JonesTrading assumed coverage on Vogenx in a report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price target on the stock. Finally, WBB Securities assumed coverage on Vogenx in a research note on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Strong Buy” and an average target price of $48.50.

About Vogenx

Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.

The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.

Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.